Q1 2022

Filed May 16, 2022 · 10-Q · 46 days after period end · 0001493152-22-013539

Q1 2022 · 10-Q

Revenue—

Net Income

-$5.44M

N/M vs Q1 2021

EPS, diluted—

Operating Income-$5,442,000N/M

Operating Cash Flow-$5,215,000N/M

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	—	$0.00	$0.00	$0.00
Net Income	-$5.44M	-$29.68M	-$1.71M	-$4.51M
EPS Diluted	—	-$1.83	-$0.02	-$0.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR